Sofwave Synchronous Ultrasound Parallel Beam (SUPERB) | Top Medtech Startup 2022

MedTech Outlook Magazine

Sofwave Synchronous Ultrasound Parallel Beam (SUPERB)
Taking Non-Invasive Aesthetic Treatment to the Next Level

Louis Scafuri, CEO, Sofwave Synchronous Ultrasound Parallel Beam (SUPERB)Louis Scafuri, CEO
Aesthetic medicine has been incredibly successful in advancing cosmetic and beauty treatments through leading-edge technologies to treat aging signs, like fine lines, wrinkles, or crow’s feet. The domain is now advancing beyond the familiar Botox to bring forth a new era of non-invasive aesthetic treatments with a hard no to needles.

Medical equipment manufacturing company Sofwave’s proprietary next-generation ultrasound technology, Synchronous Ultrasound Parallel Beam (SUPERB), is achieving this remarkable feat in the evolution of non-invasive skin rejuvenation treatments.

Sofwave is an FDA-cleared, non-invasive aesthetic treatment technology that revitalizes the skin by regenerating and increasing collagen and elastin fibers. It improves facial appearance by reducing fine lines and wrinkles and provides a lifting effect to the eyebrows, neck, and submental region without requiring needles, incisions, or anesthesia.

Sofwave’s unique applicator has seven individual ultrasound transducers that allow direct contact with the skin surface. It provides an array of high-intensity, high-frequency, and parallel ultrasound beams, which generate the right temperature at the right depth for wrinkle treatment (at a depth of 1.5 mm in the mid-dermis). SUPERB delivers a broader tissue impact, eventually leading to more collagen remodeling.
It also has an integrated cooling mechanism, Sofcool, which protects the epidermis and the layers underneath the dermis.

“No matter the skin type or color, Sofwave delivers the best results while keeping the comfort of aesthetic providers and patients in mind,” states Louis Scafuri, CEO of Sofwave.

Convenience is the name of the game for Sofwave. Patients can receive a full-face treatment within 45 minutes. The treatment seamlessly fits into an active lifestyle, and patients can return to their daily activities swiftly after. Adding to it is the treatment’s efficacy; results can be seen within two weeks of the treatment. Most patients were categorized as “improved” to “very much improved” after just one Sofwave treatment session during the clinical study.

No matter the skin type or color, Sofwave delivers the best results while keeping the comfort of aesthetic providers and patients in mind

At the core of such a futuristic solution is a group of industry experts with decades of expertise in pioneering and introducing some highly acclaimed state-of-the-art technologies in the aesthetic treatment space, including microneedling and ablative CO2 lasers. The management team’s vast experience, coupled with their collaboration with an extensive worldwide network of key thought leaders, makes Sofwave one of the most sought-after technologies in the aesthetic treatment market.

Sofwave is on the fast track to growth in North America, the Philippines, Korea, Japan, and Taiwan, along with countries in Europe, the Middle East, and Africa. Sofwave is focusing on extending its technology by adding applications for acne treatment, scar reduction, cellulite removal, and body, which are currently undergoing FDA-controlled clinical studies. Sofwave intends to remain at the helm of the non-invasive skin treatment domain with these developments.

Top 10 Medtech Startups - 2022

Company
Sofwave Synchronous Ultrasound Parallel Beam (SUPERB)

Management
Louis Scafuri, CEO

Description
Sofwave is an emerging aesthetic device company that has developed a breakthrough FDA-cleared non-invasive aesthetic technology, Synchronous Ultrasound Parallel Beam (SUPERB). It improves the facial appearance by reducing fine lines and wrinkles and provides a lifting effect to the eyebrows, neck, and submental region.

Sofwave Synchronous Ultrasound Parallel Beam (SUPERB) News

Sofwave™ Granted FDA Clearance For Latest Innovation: The "Precise" SUPERB™ Applicator

• “Precise” delivers the same SUPERB™ technology in a compact applicator head for more convenient and precise treatment of smaller curved areas, such as around the eyes and mouth
• The modular, smaller applicator head and its benefits are a direct add-on feature requiring no modification to current SUPERB™ console systems
SAN CLEMENTE - Sofwave Medical Ltd, announced today receipt of U.S. Food and Drug Administration (FDA) clearance of the Company’s 510(k) notification submission for its “Precise” compact SUPERB™ applicator to improve facial lines and wrinkles, lift the eyebrow, and lift lax submental (beneath the chin) and neck tissue; which can also affect the appearance of lax tissue in the submental and neck regions. The “Precise” applicator is also FDA cleared for short-term improvement in the appearance of cellulite.
“Following the recent FDA clearance of Sofwave’s SUPERB™ technology for the short-term improvement of cellulite last December, we are delighted to introduce the new “Precise” applicator to existing and prospective customers,” said Louis Scafuri, CEO of Sofwave Medical. “The compact applicator transducer array delivers the same safe and effective Synchronous Ultrasound Parallel Beam technology of existing large size applicators, but has been further refined with a condensed transducer configuration for more precise and convenient delivery of pulses around small, curved areas, such as the eyes and mouth. We expect this enhanced feature set and applicator configuration will be well received by Sofwave customers, and intend to leverage the new Precise applicator in additional indications in the future.”
Sofwave’s SUPERB™ System consists of two main functional components: 1) the console and 2) the applicator. The console includes the power sources, cooling unit, electrical components and the user interface. The applicator is comprised of an array of ultrasonic transducers that emit continuous acoustic waves and an active cooling element that is used to cool the skin area in contact with the applicator’s transducers.
“We continue to add functional yet transformational feature sets to the initial SUPERB™ platform’s design,” said Dr. Shimon Eckhouse, Chairman & Co-Founder. “The Precise SUPERB ™ will enable treatment of hard to reach anatomical sites with the ability to accurately target the area of treatment and with a superior ergonomic design while delivering the same safe, comfortable and highly effective treatment.”